Next Article in Journal
Diverse Marine T4-like Cyanophage Communities Are Primarily Comprised of Low-Abundance Species Including Species with Distinct Seasonal, Persistent, Occasional, or Sporadic Dynamics
Next Article in Special Issue
Post-COVID Syndrome in Adults—An Overview
Previous Article in Journal
Human Coronavirus OC43 as a Low-Risk Model to Study COVID-19
Previous Article in Special Issue
Post-COVID-19 Syndrome Comprehensive Assessment: From Clinical Diagnosis to Imaging and Biochemical-Guided Diagnosis and Management
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Viruses
Volume 15
Issue 2
10.3390/v15020579
viruses-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

High Prevalence of Alternative Diagnoses in Children and Adolescents with Suspected Long COVID—A Single Center Cohort Study

by
Sarah C. Goretzki
1,2,3,*,
Maire Brasseler
1,2,3,
Burcin Dogan
1,3,
Tom Hühne
1,
Daniel Bernard
1,
Anne Schönecker
4,
Mathis Steindor
4,
Andrea Gangfuß
1,2,
Adela Della Marina
1,2,
Ursula Felderhoff-Müser
1,2,
Christian Dohna-Schwake
1,2,3 and
Nora Bruns
1,2
1
Department of Pediatrics I, Neonatology, Pediatric Intensive Care, Pediatric Infectiology, Pediatric Neurology, University Duisburg-Essen, Children’s Hospital Essen, 45147 Essen, Germany
2
Center for Translational Neuro- and Behavioral Sciences C-TNBS, University Duisburg-Essen, 45147 Essen, Germany
3
West German Centre for Infectious Diseases (WZI), University Hospital Essen, University Duisburg-Essen, 45147 Essen, Germany
4
Department of Pediatrics III, Pediatric Pulmonology and Sleep Medicine, University Duisburg-Essen, Children’s Hospital Essen, 45147 Essen, Germany
*
Author to whom correspondence should be addressed.
Viruses 2023, 15(2), 579; https://doi.org/10.3390/v15020579
Submission received: 23 December 2022 / Revised: 31 January 2023 / Accepted: 18 February 2023 / Published: 20 February 2023
(This article belongs to the Special Issue Post-COVID Syndrome)
Browse Figures
Review Reports Versions Notes

Abstract

:
Background: Long COVID (LC) is a diagnosis that requires exclusion of alternative somatic and mental diseases. The aim of this study was to examine the prevalence of differential diagnoses in suspected pediatric LC patients and assess whether adult LC symptom clusters are applicable to pediatric patients. Materials and Methods: Pediatric presentations at the Pediatric Infectious Diseases Department of the University Hospital Essen (Germany) were assessed retrospectively. The correlation of initial symptoms and final diagnoses (LC versus other diseases or unclarified) was assessed. The sensitivity, specificity, negative and positive predictive values of adult LC symptom clusters were calculated. Results: Of 110 patients, 32 (29%) suffered from LC, 52 (47%) were diagnosed with alternative somatic/mental diseases, and 26 (23%) remained unclarified. Combined neurological and respiratory clusters displayed a sensitivity of 0.97 (95% CI 0.91–1.00) and a negative predictive value of 0.97 (0.92–1.00) for LC. Discussion/Conclusions: The prevalence of alternative somatic and mental diseases in pediatric patients with suspected LC is high. The range of underlying diseases is wide, including chronic and potentially life-threatening conditions. Neurological and respiratory symptom clusters may help to identify patients that are unlikely to be suffering from LC.

1. Introduction

Generally, children and adolescents are not severely affected by acute COVID-19, many even remaining asymptomatic [1]. However, varieties of post-infectious conditions have been described, including neurological or cognitive dysfunctions such as fatigue or loss of smell and taste. These post-infectious symptoms, named Long COVID (LC), Post COVID syndrome (PC) or post-acute sequelae SARS-CoV-2 infection (PASC) occur at all ages and can seriously limit daily life [2].
LC is less frequent in children than in adults and the prevalence is higher in girls than in boys [3]. Even though LC was acknowledged early as an emerging public health problem in children and adolescents, a Delphi consensus definition by the WHO was only published at the end of the year 2021 [4]. This may partially explain the wide range of reported prevalence of LC in pediatric patients of between 1 and 13% [5].
While potential explanatory patho-mechanisms for the development of LC have been described, no diagnostic biomarker for LC has been identified [6,7,8,9,10]. The thorough exclusion of other underlying somatic or psychiatric diseases that might cause the presented symptoms is an essential part of the work-up in suspected LC. However, LC may also involve, worsen or lead to other illness, e.g., psychiatric diseases. It may not always be possible to clearly distinguish the cause and consequence of intertwined somatic and psychiatric illness associated with SARS-CoV-2 and LC.
In the context of clinical identification of adult LC patients, symptom clusters associated with these conditions have been reported. However, these clusters frequently overlap and fluctuate over time [11]. The main clusters observed are neurological, respiratory and systemic inflammatory/abdominal [11,12,13,14]. Whether these clusters also apply to the pediatric population is under debate, potentially complicating and delaying the diagnosis of LC. In addition, to our knowledge, there is very limited literature on the nature and frequency of alternative diagnoses found in children and adolescents with suspected LC.
The aim of this study was to determine the rate of suspected LC patients who suffer from other diseases and to investigate whether symptom clusters described in adults also apply to pediatric patients. For this purpose, we analyzed initial symptoms at presentation and the final diagnosis of pediatric patients referred to our Long COVID outpatient department with suspected LC.

2. Materials and Methods

Study design and population
This is a retrospective single-center cohort study from a tertiary care center (University Hospital Essen, Germany) including patients under 18 years with a proven history of SARS-CoV-2 infection referred to the Long COVID outpatient department between 1 April 2021 and 30 September 2022 with suspected LC.
Referrals and treatment at the Long COVID outpatient department
Soon after the onset of the pandemic, repeated inquiries for pediatric patients with post-SARS-CoV-2-infection symptoms reached the Pediatric Infectious Disease Department for detailed assessment. Patients were referred from pediatricians, family physicians, primary care physicians and outpatient and inpatient pediatric specialists (Figure 1).
In the early phase of the pandemic, all referral requests were accepted. From January 2021 onwards, patients were triaged after consultation with the referring physicians: acutely ill patients were referred directly to the emergency department at our center. Urgent cases who could not be treated due to limited capacities were referred to emerging Long COVID Outpatient Departments in the surrounding areas. From May 2022 onward, triage included a standardized questionnaire by the German Society of Pediatrics (Deutsche Gesellschaft für Kinder- und Jugendmedizin, DGKJ, Appendix B, Figure 2) which was adjusted by the local physicians [15,16,17,18]. No more than 90 patients per year were treated due to limited capacities (Figure 1).
Verification of SARS-CoV-2 infections and routine diagnostic work-up
All SARS-CoV-2 infections were verified by detection of SARS-CoV-2 IgG and, in vaccinated patients, by the breakdown of SARS-CoV-2 IgG to N and S.
Routine interdisciplinary pediatric subspecialty consultations for all patients comprised specialist of pediatric infectious disease, pediatric pulmonology, pediatric cardiology, pediatric psychiatry or psychosomatics, ophthalmology, and pediatric neurology. Additional consultations were performed if indicated clinically or by exam results. Symptom-oriented instrumental examinations included electroencephalogram, electrocardiogram, echocardiography, abdominal and thyroid ultrasound, chest radiography, lung function assessment including lung clearance index measurement, cranial or spinal magnetic resonance imaging, and nerve conduction velocity, among others.
Self-reported symptoms
Amenorrhea was defined as at least three consecutive missed menstrual cycles. Exercise intolerance was defined as a pathological score in the six minutes walking test (pathological testing equaled: discontinuation due to persisting discomfort, tachycardia, drop in saturation, hypo/hypertension, pathological blood gas analysis). Furthermore a detailed medical history including Post-Exertional Malaise (PEM) Scoring was undertaken in patients with self-reported symptoms of exercise intolerance [19,20].
Data acquisition
The origin of referral, initial symptoms, preexisting conditions, demographics and physical findings were documented on a standardized protocol by the attending physician. Laboratory results (supplementary material, Appendix A), instrumental examinations and findings of interdisciplinary consultations were retrieved from the electronic patient record.
Definition of long COVID
Long-COVID syndrome was defined according to AWMF criteria [21]. NICE criteria for post-COVID condition were additionally assessed [11] (Appendix B, Table A1). Patients who fulfilled AWMF criteria were defined as LC positive if there was no other condition that could explain the symptoms. Patients who did not fulfill AWMF criteria and had another disease diagnosed during the diagnostic process were defined as LC negative. Patients who fulfilled AWMF criteria but had another disease that could explain the symptoms were defined as unclear (Figure 2).
Statistical analyses
Continuous variables are presented as mean and 95% confidence intervals (CI) or standard deviation (SD) if normally or symmetrically distributed and as median and interquartile range (IQR) if skewed. Discrete variables are presented as counts and relative frequencies. Percentages were rounded to integers because of the small total number of observations.
Descriptive statistics were performed for all three subgroups. For further analyses, the group of unclear cases was excluded and the group with clear diagnosis of LC was compared to the group with clear differential diagnoses.
Relative risks and exact 95% CIs were calculated for the registered symptoms to compare the association of symptoms with LC. Symptom clusters that have been reported in adult medicine (neurological, abdominal, respiratory) were calculated and the number of present symptoms for each cluster was counted [12,14]. Receiver operating curves (ROC) and areas under the curve (AUC) with 95% CIs (Wald) were calculated for each cluster using binary logistic regression with LC diagnosis as outcome. Because the discriminatory performance of the abdominal cluster was poor, this cluster was not further investigated.
After frequency analyses of the subgroups for the neurological and respiratory clusters, a data-driven cut off was chosen for ≤2 points vs. >2 points to calculate binary variables if the cluster was “positive” or “negative”. An additional overarching cluster was calculated with positivity of either the neurological or respiratory cluster defining positivity in the combined cluster, and negativity of both the neurological and respiratory cluster defining negativity. Sensitivity, specificity, positive predictive values (PPV), and negative predictive values (NPV) with 95% CIs (Wald) were calculated for all three clusters.SAS Enterprise Guide 8.4 (SAS Institute Inc., Cary, NC, USA) was used to perform statistical analyses and produce figures.
Ethics approval
The Ethics Committee of the Medical Faculty of the University of Duisburg-Essen approved the study (22-10581-BO). Patient informed consent was waived according to local legislation on retrospective analyses of anonymized data.

3. Results

Of 110 patients who presented at our outpatient department, 32 were diagnosed with LC according to AWMF criteria, 21 fulfilled LC criteria but had an additional disease that could explain the symptoms at least partially, and 52 patients did not fulfill LC criteria and were subsequently diagnosed with another somatic or psychiatric disease (Figure 2). The agreement between AWMF and NICE criteria was 100% across all subgroups of patients.
The majority (54%) of patients were referred to our department by pediatricians and originated from across North Rhine-Westphalia and beyond (Figure 3). However, most patients’ residencies had geographic proximity to the hospital.
Mean age at presentation was 12.7 years (152 ± SD 41.33 month) and 41% were male. Patients who had an alternative diagnosis were younger, had less health care system contacts before presentation and displayed lower prevalence of mental illness, depressive symptoms, and suicidal thoughts than LC patients and those who remained unclear (Table 1). Symptoms at presentation included neurological, respiratory, abdominal and unspecific general symptoms as well as psychiatric symptoms (Table 2). The alternative diseases ranged from SARS-CoV-2 associated, autoimmune or neuropediatric diseases to other infections, bronchial asthma or others (Table 3).
16 (15%) patients had been vaccinated against SARS-CoV-2 (Table 1). Except for patients who suffered from residuals after Pediatric Inflammatory Multisystem Syndrome temporarily associated with SARS-CoV-2 (rPIMS-TS), none of the patients had been treated during acute disease or admitted to a hospital (Table 1).
The relative risk of having LC versus another disease was higher when neurological and respiratory symptoms were present, except for cough, whereas in patients with unspecific general symptoms another disease was more likely.
ROC analyses of the calculated symptom clusters showed poor performance of the abdominal cluster (AUC 0.63 (95% CI 0.51–0.74). The neurological cluster had an AUC of 0.84 (0.75–0.93) and the respiratory cluster 0.78 (0.69–0.88). Sensitivity and specificity varied, with higher sensitivity for the neurological cluster (0.75 (95% CI 0.60–0.90)) and higher specificity of the respiratory cluster (0.83 (0.72–0.93)) (Table 4). The negative predictive values of both clusters were higher than the positive predictive values. The combined neurological and respiratory cluster showed an excellent sensitivity of 0.97 (95% CI 0.91–1.00) and a negative predictive value of 0.97 (0.92–1.00) (Table 4).
To facilitate quick screening for potential LC, we developed a simple checklist that relies on the combination of the neurological and respiratory cluster to assess the probability of LC versus a differential diagnosis (Figure 3 and Figure 4). If both clusters are negative, the probability of not having LC is 97%.

4. Discussion

This study confirmed a high prevalence of alternative diagnoses in children and adolescents with suspected LC. Of 110 pediatric patients with suspected LC, only one fourth actually fulfilled the definite diagnosis LC and half of the patients were diagnosed with an alternative somatic or psychiatric disease. Another fourth fulfilled LC criteria but had concomitant diseases that could partly explain the symptoms. In contrast to studies conducted in adult patients, none of our patients had a preexisting cardiovascular disease, diabetes or kidney disease [22]. The self-reported duration of the acute SARS-CoV-2 infection did not differ between patients with LC or other diagnoses, contrary to reports from adult studies [23]. As no patient was seriously ill during the acute infection, the influence of disease severity could not be assessed in this study.
Currently, differential diagnoses of LC are mainly discussed in the context of practice guidelines for adults, children and adolescents with LC, but evidence on their prevalence is scarce in adults and absent in children and adolescents [24,25,26]. This study found a large spectrum of differential diagnoses in children and adolescents with suspected LC, ranging from direct sequel by the SARS-CoV-2 virus itself such as residual symptoms after PIMS-TS or myocarditis, to neurological diseases, acute infections, autoimmune diseases and bronchial asthma. In addition, the prevalence of mental disorders was high in our cohort including somatization disorders, depression, anxiety and eating disorders.
At least a quarter of adult patients display concomitant mental illnesses with LC [27,28,29]. A potential explanation for this frequent joint occurrence is the theory that COVID-induced high inflammatory activity of the immune system might promote depression [30]. However, the impact of social isolation, loss of hobbies, interactions with peers, face-to-face teaching, etc. on children and adolescents as a result of preventive measures during the pandemic must not be omitted [31,32,33].
The most important finding of this study is that the high prevalence of alternative diseases in children and adolescents with suspected LC makes extensive somatic and psychiatric diagnostics indispensable to exclude potentially life-threatening acute and chronic diseases. Under no circumstances should LC be diagnosed or treatment initiated without comprehensive diagnostic work, in order to avoid treatment delay of an underlying severe somatic or psychiatric disease.
It is highly relevant that patients with a high likelihood of suffering from an alternative disease are identified quickly in order to initiate adequate diagnostics and therapy. In this cohort, general symptoms, other than chest pain and amenorrhea, were not specific for LC. In contrast, neurological and respiratory symptoms except for cough frequently described in adults with LC were also associated with LC in this pediatric cohort. Regarding abdominal symptoms, rPIMS-TS patients may have introduced bias, which makes the findings of relative risks for abdominal symptoms difficult to interpret. To further investigate the association of clinical symptom patterns and LC, we examined adult symptom clusters regarding their ability to identify or rule out pediatric LC [12,14]. In line with reports on adult patients we found that the neurological and respiratory clusters applied also to pediatric LC patients, whereas unspecific symptoms and the abdominal cluster were not associated with LC [4,34]. The high sensitivity of the respiratory and neurological clusters in identifying LC and, even more importantly, the excellent negative predictive value of the combined clusters may be of practical value in the future to quickly identify patients who are likely to suffer from an alternative disease and require extensive diagnostic work-up. However, use of the checklist does not exempt the attending physician from a thorough medical workup.
There was a group of patients in this study, however, in whom it could not be determined whether residuals of the infection with SARS-CoV-2 caused the complaints or whether it aggravated an underlying disease. This group needs to be further investigated because, contrary to adult patients, there is no evidence as to which underlying diseases predispose children to develop LC [35]. In clinical practice, these patients do not fit into the standard health care system and therefore are in special need of a multi-professional team to rule out differential diagnoses, organize follow-up visits and supportive treatments such as physiotherapies [36].
There are several limitations to this study. The limited capacity of our Long COVID outpatient department (maximum 90 patients per year) potentially resulted in a selection bias towards severe cases. This pre-selected patient population had a high symptom burden and thus a high probability of LC or other diseases. Only five patients had neither LC nor a somatic/psychiatric disease, which does not represent the general pediatric population. Due to the pre-selection, the prevalence of LC may be overestimated by our study. The direct referrals of patients with unambiguous gastroenterological or rheumatological symptoms to the corresponding outpatient departments likely enhanced this phenomenon. In addition, this is a single-center study, which further limits representativeness.
Another important aspect to discuss is the reason why many differential diagnoses were not detected at earlier time points. This may be due to the fact that symptoms of LC are heterogeneous, often vague and broad. For example, Visler et al. describe that more than 200 symptoms can be assigned to the diagnosis of LC []. Furthermore, it is an exclusion diagnosis without established diagnostic biomarkers [37]. Therefore, symptoms may be falsely attributed to LC. In addition, during the pandemic, regular screenings were partially omitted or postponed, potentially delaying the diagnosis of somatic and psychiatric diseases.

5. Conclusions

In this study, children and adolescents with suspected LC have a high prevalence of alternative somatic and mental diseases. The range of differential diagnoses includes severe and potentially life-threatening diseases from nearly all pediatric subspecialties. Diagnosis of LC should only be made or “symptomatic” therapy initiated with prior exclusion of other diseases. Using clinical criteria and the adult neurological and respiratory LC clusters, it is possible to identify patients with low probability of LC early and diagnose them in detail.

Author Contributions

Study conceptualization and methodology: S.C.G., C.D.-S. and N.B.; Validation and formal analysis: S.C.G., C.D.-S., M.B. and N.B.; Acquisition of data: S.C.G., M.B., B.D., T.H. and D.B.; Writing draft preparation: S.C.G., C.D.-S. and N.B.; writing-review and editing: S.C.G., C.D.-S., N.B., B.D., M.S., M.B., A.S., A.G., A.D.M. and U.F.-M. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki, and approved by the Ethics Committee of the Medical Faculty of the University of Duisburg-Essen approved the study (22-10581-BO).

Informed Consent Statement

Patient informed consent was waived according to local legislation on retrospective analyses of anonymized data.

Data Availability Statement

Not applicable.

Acknowledgments

We thank our patients and their families for the trust they have placed in us. We would also like to thank our colleagues in pediatric cardiology, pediatric pneumology, neuropediatric, pediatric endocrinology, gastroenterology, immunology, rheumatology and hematology/oncology who have always supported us with great personal commitment in the care. Furthermore, we would like to thank our colleagues of the psychosomatic department, as well as the colleagues of the child and adolescents for all the acute appointments that were made possible. The authors thank all the nurses of the pediatric infectious outpatient ward of the University Hospital Essen, Germany for their help during patient’s visits.

Conflicts of Interest

The authors declare no conflict of interest.

Appendix A

Standard diagnostics test performed for every patient
Blood workup: differential blood count, TPZ, INR, aPTT, thrombin time, fibrinogen, antithrombin-III, d-dimer, electrolytes, potassium, phosphate, creatinine, cystatin-C, urea, CK, CK-MB, troponin T, myoglobin, NT-pro BNP, transaminases, LDH, CRP, triglycerides, C3, C4, haptoglobin, IgA/M/G/E, blood sedimentation, blood gas analysis, Cortisol, TSH, fT4, SARS-CoV-2-IgG (for vaccinated this was broken down to N and S).
Additional tests performed for patients seen after 11/2021: 25-OH-vitamin D, vitamins B1, B6, and B12, folate and sprue diagnostics, ferritin, ANA, ANCA.
Standard urinalysis: Status and Microscopy.
Additional tests performed for patients seen after 11/2021: 24-h Cortisol levels in the Urine.
The laboratory diagnostics were expanded in a symptom-oriented manner.

Appendix B

Viruses 15 00579 g0a1 550
Figure A1. Checklist for the survey of symptom clusters in suspected Long COVID in children and adolescents.
Figure A1. Checklist for the survey of symptom clusters in suspected Long COVID in children and adolescents.
Viruses 15 00579 g0a1
Viruses 15 00579 g0a2a 550Viruses 15 00579 g0a2b 550Viruses 15 00579 g0a2c 550
Figure A2. Questionnaire in the context of the initial presentation in case of suspicion of pediatric Long-COVID.
Figure A2. Questionnaire in the context of the initial presentation in case of suspicion of pediatric Long-COVID.
Viruses 15 00579 g0a2aViruses 15 00579 g0a2bViruses 15 00579 g0a2c
Table
Table A1. Used Definitions for LC.
Table A1. Used Definitions for LC.
Summary of Used Definition
AWMF Long COVID [20]
  • Persisting symptoms after acute COVID-19 or its treatment
  • Symptoms leading to a new health impairment
  • New symptoms that appeared after the end of the acute phase as a result of COVID-19 disease
worsening of a pre-existing underlying condition
NICE Post COVID [11]
  • Ongoing symptomatic signs and symptoms that developed during COVID-19 and have no other explanation from 4 weeks up to 12 weeks after the acute infection
>12 weeks = Post COVID Syndrome. It usually presents with clusters of symptoms, often overlapping, which can fluctuate and change over time and can affect any system in the body.
Delphi Post COVID-19 condition [4]
  • PMost COVID condition occurs in individuals with a history of probable or confirmed SARS-CoV-2 infection, usually 3 months from the onset, with symptoms that last for at least 2 months and cannot be explained by an alternative diagnosis.

References

  1. Swann, O.V.; Holden, K.A.; Turtle, L.; Pollock, L.; Fairfield, C.J.; Drake, T.M.; Seth, S.; Egan, C.; Hardwick, H.E.; Halpin, S.; et al. Clinical characteristics of children and young people admitted to hospital with COVID-19 in United Kingdom: Prospective multicentre observational cohort study. BMJ 2020, 370, m3249. [Google Scholar] [CrossRef] [PubMed]
  2. Brugler Yonts, A. Pediatric Long-COVID: A Review of the Definition, Epidemiology, Presentation, and Pathophysiology. Pediatr. Ann. 2022, 51, e416–e420. [Google Scholar] [CrossRef] [PubMed]
  3. Rao, S.; Lee, G.M.; Razzaghi, H.; Lorman, V.; Mejias, A.; Pajor, N.M.; Thacker, D.; Webb, R.; Dickinson, K.; Bailey, L.C.; et al. Clinical Features and Burden of Postacute Sequelae of SARS-CoV-2 Infection in Children and Adolescents. JAMA Pediatr. 2022, 176, 1000–1009. [Google Scholar] [CrossRef] [PubMed]
  4. Soriano, J.B.; Murthy, S.; Marshall, J.C.; Relan, P.; Diaz, J.V.; WHO Clinical Case Definition Working Group on Post-COVID-19 Condition. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect. Dis. 2022, 22, e102–e107. [Google Scholar] [CrossRef] [PubMed]
  5. Vilser, D. Long Covid/Post-COVID-19-Syndrom bei Kindern und Jugendlichen. Pädiatrie 2022, 34, 20–25. [Google Scholar] [CrossRef]
  6. Nalbandian, A.; Sehgal, K.; Gupta, A.; Madhavan, M.V.; McGroder, C.; Stevens, J.S.; Cook, J.R.; Nordvig, A.S.; Shalev, D.; Sehrawat, T.S.; et al. Post-acute COVID-19 syndrome. Nat. Med. 2021, 27, 601–615. [Google Scholar] [CrossRef]
  7. Crook, H.; Raza, S.; Nowell, J.; Young, M.; Edison, P. Long covid-mechanisms, risk factors, and management. BMJ 2021, 374, n1648. [Google Scholar] [CrossRef]
  8. Son, K.; Jamil, R.; Chowdhury, A.; Mukherjee, M.; Venegas, C.; Miyasaki, K.; Zhang, K.; Patel, Z.; Salter, B.; Yuen, A.C.Y.; et al. Circulating anti-nuclear autoantibodies in COVID-19 survivors predict long-COVID symptoms. Eur. Respir. J. 2023, 61, 22009700. [Google Scholar] [CrossRef]
  9. Chioh, F.W.; Fong, S.W.; Young, B.E.; Wu, K.X.; Siau, A.; Krishnan, S.; Chan, Y.H.; Carissimo, G.; Teo, L.L.; Gao, F.; et al. Convalescent COVID-19 patients are susceptible to endothelial dysfunction due to persistent immune activation. eLife 2021, 10, e64909. [Google Scholar] [CrossRef]
  10. Kubánková, M.; Hohberger, B.; Hoffmanns, J.; Fürst, J.; Herrmann, M.; Guck, J.; Kräter, M. Physical phenotype of blood cells is altered in COVID-19. Biophys. J. 2021, 120, 2838–2847. [Google Scholar] [CrossRef]
  11. Venkatesan, P. NICE guideline on long COVID. Lancet Respir. Med. 2021, 9, 129. [Google Scholar] [CrossRef] [PubMed]
  12. Canas, L.; Molteni, E.; Deng, J.; Sudre, C.H.; Murray, B.; Kerfoot, E.; Antonelli, M.; Chen, L.; Rjoob, K.; Pujol, J.C.; et al. Profiling post-COVID syndrome across different variants of SARS-CoV-2. medRxiv 2022. [CrossRef]
  13. Wong-Chew, R.M.; Rodríguez Cabrera, E.X.; Rodríguez Valdez, C.A.; Lomelin-Gascon, J.; Morales-Juárez, L.; de la Cerda, M.L.R.; Villa-Romero, A.R.; Arce Fernández, S.; Serratos Fernandez, M.; Bello, H.H.; et al. Symptom cluster analysis of long COVID-19 in patients discharged from the Temporary COVID-19 Hospital in Mexico City. Ther. Adv. Infect. Dis. 2022, 9, 20499361211069264. [Google Scholar] [CrossRef]
  14. AlAly, Z.; Xie, Y.; Bowe, B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature 2021, 594, 259–264. [Google Scholar] [CrossRef]
  15. Available online: https://www.dgkj.de/fileadmin/user_upload/Meldungen_2022/Long_COVID_B%C3%B6gen/2_Long_COVID_Einschaetzung_der_Dringlichkeit_.pdf (accessed on 15 December 2022).
  16. Available online: https://www.dgkj.de/fileadmin/user_upload/Meldungen_2022/Long_COVID_B%C3%B6gen/3_Long_COVID_Allgemeine_Anamnese_.pdfDGPI (accessed on 15 December 2022).
  17. Available online: https://www.dgkj.de/fileadmin/user_upload/Meldungen_2022/Long_COVID_B%C3%B6gen/4_Long_COVID_Spezielle_Anamnese_.pdf (accessed on 15 December 2022).
  18. Tenenbaum, T.; Hufnagel, M.; Knuf, M.; Kobbe, P.D.R.; Neubert, P.D.J.; Renk, H.; Rudolph, H.; Töpfner, N.; Janda, A.; von Bernuth, H.; et al. Stellungnahme der DGPI, API, DGKJ, DGPK, GPOH, GKJR, GPP und STAKOB zur Klinik, Diagnostik und Therapie von Kindern mit COVID-19-Update Februar 2022. Available online: https://dgpi.de/klinik-diagnostik-therapie-kinder-mit-covid-feb-2022/ (accessed on 15 December 2022).
  19. Cotler, J.; Holtzman, C.; Dudun, C.; Jason, L.A. A Brief Questionnaire to Assess Post-Exertional Malaise. Diagnostics 2018, 8, 66. [Google Scholar] [CrossRef] [Green Version]
  20. Koczulla, A.R.; Ankermann, T.; Behrends, U.; Berlit, P.; Böing, S.; Brinkmann, F.; Franke, C.; Glöckl, R.; Gogoll, C.; Hummel, T.; et al. S1 Guideline Post-COVID/Long-COVID. Pneumologie 2021, 75, 869–900. [Google Scholar] [CrossRef]
  21. Töpfner, N.; Alberer, M.; Ankermann, T.; Bender, S.; Berner, R.; de Laffolie, J.; Dingemann, J.; Heinicke, D.; Haas, J.P.; Hufnagel, M.; et al. Einheitliche Basisversorgung von Kindern und Jugendlichen mit Long COVID. Mon. Kinderheilkd. 2022, 170, 539–547. [Google Scholar] [CrossRef]
  22. Sahu, A.K.; Mathew, R.; Aggarwal, P.; Nayer, J.; Bhoi, S.; Satapathy, S.; Ekka, M. Clinical Determinants of Severe COVID-19 Disease—A Systematic Review and Meta-Analysis. J. Glob. Infect. Dis. 2021, 13, 13–19, PMCID:PMC8054797. [Google Scholar] [CrossRef] [PubMed]
  23. Castanares-Zapatero, D.; Chalon, P.; Kohn, L.; Dauvrin, M.; Detollenaere, J.; Maertens de Noordhout, C.; Primus-de Jong, C.; Cleemput, I.; Van den Heede, K. Pathophysiology and mechanism of long COVID: A comprehensive review. Ann. Med. 2022, 54, 1473–1487, PMCID:PMC9132392. [Google Scholar] [CrossRef] [PubMed]
  24. Sisó-Almirall, A.; Brito-Zerón, P.; Conangla Ferrín, L.; Kostov, B.; Moragas Moreno, A.; Mestres, J.; Sellarès, J.; Galindo, G.; Morera, R.; Basora, J.; et al. Long Covid-19: Proposed Primary Care Clinical Guidelines for Diagnosis and Disease Management. Int. J. Environ. Res. Public Health 2021, 18, 4350. [Google Scholar] [CrossRef]
  25. Pilotto, A.; Cristillo, V.; Cotti Piccinelli, S.; Zoppi, N.; Bonzi, G.; Sattin, D.; Schiavolin, S.; Raggi, A.; Canale, A.; Gipponi, S.; et al. Long-term neurological manifestations of COVID-19: Prevalence and predictive factors. Neurol. Sci. 2021, 42, 4903–4907. [Google Scholar] [CrossRef]
  26. Mazza, M.G.; Palladini, M.; De Lorenzo, R.; Magnaghi, C.; Poletti, S.; Furlan, R.; Ciceri, F.; Rovere-Querini, P.; Benedetti, F.; COVID-19 BioB Outpatient Clinic Study group. Persistent psychopathology and neurocognitive impairment in COVID-19 survivors: Effect of inflammatory biomarkers at three-month follow-up. Brain Behav. Immun. 2021, 94, 138–147. [Google Scholar] [CrossRef]
  27. Aiyegbusi, O.L.; Hughes, S.E.; Turner, G.; Rivera, S.C.; McMullan, C.; Chandan, J.S.; Haroon, S.; Price, G.; Davies, E.H.; Nirantharakumar, K.; et al. Symptoms, complications and management of long COVID: A review. J. R. Soc. Med. 2021, 114, 428–442. [Google Scholar] [CrossRef]
  28. Benedetti, F.; Mazza, M.; Cavalli, G.; Ciceri, F.; Dagna, L.; Rovere-Querini, P. Can Cytokine Blocking Prevent Depression in COVID-19 Survivors? J. Neuroimmune Pharmacol. 2021, 16, 1–3. [Google Scholar] [CrossRef]
  29. Buonsenso, D.; Roland, D.; De Rose, C.; Vásquez-Hoyos, P.; Ramly, B.; Chakakala-Chaziya, J.N.; Munro, A.; González-Dambrauskas, S. Schools Closures During the COVID-19 Pandemic: A Catastrophic Global Situation. Pediatr. Infect. Dis. J. 2021, 40, e146–e150. [Google Scholar] [CrossRef]
  30. Hugelius, K.; Harada, N.; Marutani, M. Consequences of visiting restrictions during the COVID-19 pandemic: An integrative review. Int. J. Nurs. Stud. 2021, 121, 104000. [Google Scholar] [CrossRef]
  31. Racine, N.; McArthur, B.A.; Cooke, J.E.; Eirich, R.; Zhu, J.; Madigan, S. Global Prevalence of Depressive and Anxiety Symptoms in Children and Adolescents During COVID-19: A Meta-analysis. JAMA Pediatr. 2021, 175, 1142–1150. [Google Scholar] [CrossRef]
  32. Wulf Hanson, S.; Abbafati, C.; Aerts, J.G.; Al-Aly, Z.; Ashbaugh, C.; Ballouz, T.; Blyuss, O.; Bobkova, P.; Bonsel, G.; Borzakova, S.; et al. Estimated Global Proportions of Individuals With Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters Following Symptomatic COVID-19 in 2020 and 2021. JAMA 2022, 328, 1604–1615. [Google Scholar] [CrossRef]
  33. Esposito, S.; Principi, N.; Azzari, C.; Cardinale, F.; Di Mauro, G.; Galli, L.; Gattinara, G.C.; Fainardi, V.; Guarino, A.; Lancella, L.; et al. Italian intersociety consensus on management of long covid in children. Ital. J. Pediatr. 2022, 48, 42. [Google Scholar] [CrossRef]
  34. Radtke, T.; Ulyte, A.; Puhan, M.A.; Kriemler, S. Long-term Symptoms After SARS-CoV-2 Infection in Children and Adolescents. JAMA 2021, 326, 869–871. [Google Scholar] [CrossRef]
  35. Sdat Larijani, M.; Ashrafian, F.; Bagheri Amiri, F.; Banifazl, M.; Bavand, A.; Karami, A.; Asgari Shokooh, F.; Ramezani, A. Characterization of long COVID-19 manifestations and its associated factors: A prospective cohort study from Iran. Microb. Pathog. 2022, 169, 105618. [Google Scholar] [CrossRef]
  36. Udina, C.; Ars, J.; Morandi, A.; Vilaró, J.; Cáceres, C.; Inzitari, M. Rehabilitation in adult post-COVID-19 patients in post-acute care with Therapeutic Exercise. J. Frailty Aging 2021, 10, 297–300. [Google Scholar] [CrossRef]
  37. Penner, J.; Abdel-Mannan, O.; Grant, K.; Maillard, S.; Kucera, F.; Hassell, J.; Eyre, M.; Berger, Z.; Hacohen, Y.; Moshal, K.; et al. 6-month multidisciplinary follow-up and outcomes of patients with paediatric inflammatory multisystem syndrome (PIMS-TS) at a UK tertiary paediatric hospital: A retrospective cohort study. Lancet Child Adolesc. Health 2021, 5, 473–482. [Google Scholar] [CrossRef]
Viruses 15 00579 g001 550
Figure 1. Referral and diagnostic procedure at the Long COVID Outpatient Department at the University Hospital Essen (see Appendix B, Figure A2 for the referral request form).
Figure 1. Referral and diagnostic procedure at the Long COVID Outpatient Department at the University Hospital Essen (see Appendix B, Figure A2 for the referral request form).
Viruses 15 00579 g001
Viruses 15 00579 g002 550
Figure 2. Flow chart of children and adolescents who attended the Long COVID Outpatient Department at the University Hospital Essen between January 2021 and September 2022 with suspected long COVID.
Figure 2. Flow chart of children and adolescents who attended the Long COVID Outpatient Department at the University Hospital Essen between January 2021 and September 2022 with suspected long COVID.
Viruses 15 00579 g002
Viruses 15 00579 g003 550
Figure 3. Heat map of referral areas of children and adolescents attended at the Long COVID Outpatient Department of the University Hospital Essen between January 2021 and September 2022 with suspected Long COVID.
Figure 3. Heat map of referral areas of children and adolescents attended at the Long COVID Outpatient Department of the University Hospital Essen between January 2021 and September 2022 with suspected Long COVID.
Viruses 15 00579 g003
Viruses 15 00579 g004 550
Figure 4. Relative risk of being diagnosed with Long COVID versus an alternative disease in children and adolescents with suspected Long COVID depending on symptoms at presentation.
Figure 4. Relative risk of being diagnosed with Long COVID versus an alternative disease in children and adolescents with suspected Long COVID depending on symptoms at presentation.
Viruses 15 00579 g004
Table
Table 1. Patient characteristics.
Table 1. Patient characteristics.
Long COVIDOther DiseaseUnclear
n = 32n = 52n = 26
Male 13 (41%)25 (48%)13 (46%)
Age (years)mean (95% CI)12.1
(10.9–13.4)		9.1
(7.5–10.8)		11.8
(10.1.–13.4)
met AWMF criteria 32 (100%)0 (0%)17 (65%)
met NICE criteria 32 (100%)0 (0%)17 (65%)
SARS-CoV-2 IgG BAU/mL
(breakdown into anti-spike(S) and anti-nucleocapsid(N) SARS-CoV-2-IgG was only carried out for vaccinated patients)		mean ± SD
IQR		1194 ± 904
1813 (268–2080)		1016 ± 950
1974 (106–2080)		911 ± 964
2013 (67–2080)
self-reported duration of acute disease (days)median
IQR		3
3 (2–5)		4
5 (3–8)		3
3 (0–4)
Time from infection to first consultation 6 (days)mean ± SD 120 ± 99 120 ± 167127 ± 130
Number of health care system contacts before presentationmean (95% CI) 3.2 (2.6–3.8) 2.0 (1.7–2.3)2.6 (1.5–3.7)
newly diagnosed somatic diseasetotal4 (1%)52 (100%)16 (62%)
SARS-CoV-2 associated diseases 10 (0%)23 (44%)0 (0%)
autoimmune diseases 20 (0%)3 (6%)0 (0%)
bacterial infections 30 (0%)5 (10%)5 (19%)
neuropaediatric diseases 41 (3%)7 (13%)3 (12%)
bronchial asthma5 (16%)6 (19%)8 (31%)
New-onset anaemia0 (0%)0 (0%)1 (0.4%)
Others 50 (0%)10 (19%)0 (0%)
newly diagnosed mental disease 14 (44%)3 (6%)12 (46%)
psychiatric symptomssuicidal thoughts4 (13%)0 (0%)3 (12%)
depression/depressive symptoms20 (63%)10 (19%)12 (46%)
SARS-CoV-2 immunisationat least 1 vaccination3 (9%)6 (12%)7 (27%)
≥2 vaccinations2 (6%)4 (8%)6 (23%)
virus wavesAlpha9 (28%)16 (31%)9 (35%)
Delta5 (16%)9 (17%)11 (42%)
omicron18 (56%)18 (35%)4 (15%)
SD = standard deviation, AWMF = German Association of the Scientific Medical Societies, NICE = National Institute for Health and Care Excellence; 1 SARS-CoV-2 associated diseases = COVID-19, rPIMS-TS, myocarditis due SARS-CoV-2-infection; 2 autoimmune diseases = dermatomyositis, rheumatoid arthritis, inflammatory bowel disease; 3 bacterial infections = pneumonia, mastoiditis, neuroborreliosis; 4 neuro-pediatric diseases = encephalitis, neuritis, myositis, Lambert Eaton/myasthenia, migraine, epilepsy; 5 Others = secondary real hypertension, ruptured ovary, immunodeficient, EBV infection, oncological primary disease, HbSS, constipation, astigmatism, parasitosis; 6 except 10 unclear infection data (2 of the group “unclear”, 8 of the group “other diagnosis”).
Table
Table 2. Symptoms at presentation.
Table 2. Symptoms at presentation.
Symptom PresentSymptom Leading *
Long COVIDOther DiseaseUnclearLong COVIDOther DiseaseUnclear
n = 32n = 52n = 26n = 32n = 52n = 26
Respiratory symptomsdyspnoea12 (38%)9 (17%)3 (12%)8 (15%)8 (25%)9 (35%)
exersice intolerance25 (78%)26 (50%)8 (31%)12 (23%)21 (66%)17 (65%)
cough1 (3%)12 (23%)0 (0%)0 (0%)0 (0%)3 (12%)
Neurological symptomsparesthesias21 (66%)22 (42%)1 (4%)0 (0%)13 (41%)14 (54%)
dysfunction of smell and taste13 (41%)1 (2%)2 (8%)9 (17%)1 (3%)5 (19%)
headaches15 (47%)9 (17%)2 (8%)0 (0%)1 (3%)10 (39%)
vertigo8 (25%)2 (4%)1 (4%)0 (0%)0 (0%)8 (31%)
brain fog19 (59%)7 (13%)0 (0%)0 (0%)1 (3%)12 (46%)
fatigue9 (28%)8 (15%)0 (0%)0 (0%)0 (0%)10 (39%)
sleep disturbance12 (38%)5 (10%)0 (0%)0 (0%)0 (0%)7 (27%)
Abdominal symptomsabdominal pain7 (22%)7 (14%)1 (4%)0 (0%)3 (9%)2 (8%)
diarrhea0 (0%)1 (2%)0 (0%)0 (0%)1 (3%)0 (0%)
General symptomsthoracic pain, palpations17 (53%)11 (21%)2 (8%)3 (6%)5 (16%)11 (42%)
hair loss1 (3%)12 (23%)0 (0%)0 (0%)11 (21%)0 (0%)
Flue-like symptoms0 (0%)8 (15%)0 (0%)0 (0%)4 (13%)0 (0%)
exanthema0 (0%)7 (13%)0 (0%)0 (0%)1 (3%)0 (0%)
lymphadenopathy0 (0%)1 (2%)0 (0%)0 (0%)1 (3%)1 (4%)
amenorrhoea9 (28%)1 (2%)0 (0%)0 (0%)0 (0%)5 (19%)
* According to patient’s perception.
Table
Table 3. Newly encountered diseases in patients with suspected long COVID *1.
Table 3. Newly encountered diseases in patients with suspected long COVID *1.
Type of DiseaseSpecific Diseasen (%)
somatic diseaseSARS-CoV-2 associated diseasesCOVID-195 (10%)
rPIMS-TS16 (31%)
myocarditis2 (4%)
autoimmune diseasesdermatomyositis1 (2%)
rheumatoid arthritis 1 (2%)
inflammatory bowel disease 1 (2%)
infections pneumonia (bacterial) 1 (2%)
neuroborreliosis 1 (2%)
EBV infection 2 (4%)
asymptomatic CMV infection *21 (2%)
parasitosis2 (4%)
localized bacterial infection2 (4%)
neuropediatric diseases neuritis 1 (2%)
Lambert Eaton syndrome/myasthenia 5 (10%)
migraine 1 (1%)
pulmonary diseasebronchial asthma6 (12%)
others secondary renal hypertension 1 (1%)
ruptured ovary 1 (1%)
immunodeficiency 2 (1%)
oncological/hematological disease 4 (8%)
constipation 1 (1%)
astigmatism 1 (1%)
Mental disease adjustment disorder/somatization disorder3 (6%)
depression1 (1%)
*1 Previously known diagnoses are not included, e.g., homozygous sickle cell anemia; *2 Considered as an incidental finding rather than the cause of the symptoms after thorough work up. rPIMS-TS = residuals of Pediatric Inflammatory Multisystem Syndrome temporarily-associated with SARS-CoV-2 EBV = Epstein-Barr virus, CMV = cytomegalovirus.
Table
Table 4. Sensitivity, specificity, and predictive values to identify patients with LC versus alternative diseases from clinical symptom clusters in suspected pediatric Long COVID.
Table 4. Sensitivity, specificity, and predictive values to identify patients with LC versus alternative diseases from clinical symptom clusters in suspected pediatric Long COVID.
Cluster
NeurologicalRespiratoryCombined *
Patients with positive cluster
LC (Ntotal = 32)24 (75%)21 (66%)31 (97%)
Non-LC (Ntotal = 52)10 (19%)9 (17%)16 (31%)
Statistical measure
Sensitivity0.75 (0.60–0.90)0.66 (0.49–0.82)0.97 (0.91–1.00)
Specifity0.81 (0.70–0.91)0.83 (0.72–0.93)0.69 (0.57–0.82)
Positive predictive value0.71 (0.55–0.86)0.70 (0.54–0.86)0.66 (0.52–0.80)
Negative predictive value0.84 (0.74–0.94)0.80 (0.69–0.90)0.97 (0.92–1.00)
* Positive if either the neurological OR the respiratory cluster applies, negative if neither cluster applies.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Goretzki, S.C.; Brasseler, M.; Dogan, B.; Hühne, T.; Bernard, D.; Schönecker, A.; Steindor, M.; Gangfuß, A.; Della Marina, A.; Felderhoff-Müser, U.; et al. High Prevalence of Alternative Diagnoses in Children and Adolescents with Suspected Long COVID—A Single Center Cohort Study. Viruses 2023, 15, 579. https://doi.org/10.3390/v15020579

AMA Style

Goretzki SC, Brasseler M, Dogan B, Hühne T, Bernard D, Schönecker A, Steindor M, Gangfuß A, Della Marina A, Felderhoff-Müser U, et al. High Prevalence of Alternative Diagnoses in Children and Adolescents with Suspected Long COVID—A Single Center Cohort Study. Viruses. 2023; 15(2):579. https://doi.org/10.3390/v15020579

Chicago/Turabian Style

Goretzki, Sarah C., Maire Brasseler, Burcin Dogan, Tom Hühne, Daniel Bernard, Anne Schönecker, Mathis Steindor, Andrea Gangfuß, Adela Della Marina, Ursula Felderhoff-Müser, and et al. 2023. "High Prevalence of Alternative Diagnoses in Children and Adolescents with Suspected Long COVID—A Single Center Cohort Study" Viruses 15, no. 2: 579. https://doi.org/10.3390/v15020579

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop